Nakajo M
Department of Radiology, Faculty of Medicine, Kagoshima University.
Kaku Igaku. 1999 Jan;36(1):1-5.
The author reviewed present status and progress of endocrine nuclear medicine including thyroid, parathyroid, adrenocortical, adrenomedullary and somatostatin receptor imaging and also radionuclide therapy of Basedow's disease, metastatic foci of post-operative thyroid cancer and malignant neural crest tumor. Relatively new imaging agents include 99mTc-MIBI and 99mTc-tetrofosmin for parathyroid imaging and 111In-pentetreotide for somatostatin receptor imaging. It is hoped that therapy of malignant neural crest tumors such as metastatic pheochromocytoma and neuroblastoma with 131I-MIBG and somatostatin receptor imaging will be available in Japan as soon as possible.
作者回顾了内分泌核医学的现状与进展，包括甲状腺、甲状旁腺、肾上腺皮质、肾上腺髓质及生长抑素受体显像，以及格雷夫斯病、术后甲状腺癌转移灶和恶性神经嵴肿瘤的放射性核素治疗。相对较新的显像剂包括用于甲状旁腺显像的99mTc-MIBI和99mTc-替曲膦，以及用于生长抑素受体显像的111In-喷曲肽。希望131I-MIBG治疗转移性嗜铬细胞瘤和神经母细胞瘤等恶性神经嵴肿瘤以及生长抑素受体显像能尽快在日本应用。
